Related Experiment Video
Updated: May 27, 2026
07:30
Homogeneous Time-resolved Förster Resonance Energy Transfer-based Assay for Detection of Insulin Secretion
Published on: May 10, 2018
[Incretin-based therapy for treating patients with type 2 diabetes]
1Fővárosi Bajcsy-Zsilinszky Kórház III. Belgyógyászati Osztály Budapest Maglódi. gyjermendy@mail.datanet.hu
Orvosi Hetilap
|November 11, 2011
Summary
New incretin-based drugs, including GLP-1 receptor agonists and DPP-4 inhibitors, offer new treatment options for type 2 diabetes, often combined with metformin.
Area of Science:
- Pharmacology
- Endocrinology
- Internal Medicine
Background:
- A new class of antidiabetic medications has recently become available.
- Intensive research has led to the market introduction of several novel drugs.
- These advancements include incretin mimetics and incretin enhancers.
Purpose of the Study:
- To review clinical experiences with new incretin-based antidiabetic drugs.
- To focus on the benefits and potential side-effects of these compounds.
- To provide insights into their use in type 2 diabetes management.
Main Methods:
- Review of clinical practice data and available literature.
- Analysis of efficacy and safety profiles of specific incretin-based drugs.
- Examination of combination therapy, particularly with metformin.
Main Results:
- GLP-1 receptor agonists (exenatide, liraglutide) and DPP-4 inhibitors (sitagliptin, vildagliptin, saxagliptin) are available.
- Linagliptin is anticipated for market introduction.
- Incretin-based drugs can be utilized in type 2 diabetes treatment, preferably with metformin.
Conclusions:
- Incretin-based therapies represent a significant advancement in type 2 diabetes management.
- Understanding the benefits and side-effects is crucial for optimal patient care.
- Combination with metformin is a preferred therapeutic strategy.
Related Concept Videos
01:24Glucagon-like Receptor Agonists
Incretins include glucagon-like peptide-1 (GLP-1) and glucose-dependent insulinotropic polypeptide (GIP), which stimulate insulin secretion post-meals. In type 2 diabetes, GIP's efficacy is reduced, making GLP-1 a viable drug target. GIP originates from preproGIP.
GLP-1, when administered in high doses intravenously, triggers insulin secretion, inhibits glucagon release, slows gastric emptying, reduces food intake, and restores normal insulin secretion. However, its rapid inactivation by the...
GLP-1, when administered in high doses intravenously, triggers insulin secretion, inhibits glucagon release, slows gastric emptying, reduces food intake, and restores normal insulin secretion. However, its rapid inactivation by the...
01:23Dipeptidyl Peptidase 4 Inhibitors
Dipeptidyl peptidase 4 (DPP-4) is a serine protease widely distributed in the body. It's involved in the inactivation of GLP-1 and GIP hormones, which are crucial for insulin regulation. DPP-4 inhibitors, such as sitagliptin (Januvia), saxagliptin (Onglyza), linagliptin (Tradjenta), alogliptin (Nesina), and vildagliptin (Galvus), help increase the proportion of active GLP-1, enhancing insulin secretion. These inhibitors work by competitively binding to DPP-4. This binding causes a significant...
01:26Oral Hypoglycemic Agents: Biguanides and Glitazones
Biguanides, particularly metformin (Glucophage), are insulin sensitizers that enhance glucose uptake, thereby reducing insulin resistance. Unlike sulfonylureas, metformin doesn't prompt insulin secretion, which helps to curb hypoglycemia risk. Metformin is beneficial in treating conditions like polycystic ovary syndrome due to its insulin-resistance reduction capability. The drug's primary action involves curtailing hepatic gluconeogenesis, a significant contributor to high blood glucose levels...
01:06Oral Hypoglycemic Agents: Glinides
Repaglinide (Prandin) and Nateglinide (Starlix), known as glinides, are oral insulin secretagogues that stimulate insulin release from pancreatic β cells by closing the ATP-sensitive potassium channels (KATP channel). Repaglinide controls insulin release from pancreatic β cells by managing potassium efflux. It shares two binding sites with sulfonylureas and also has a unique site, indicating overlapping mechanisms of action. With a rapid onset and a 4-7 hour duration, it effectively manages...
01:15Diabetes: Management and Pharmacotherapy
The therapy for diabetes aims to alleviate hyperglycemia-related symptoms, prevent acute metabolic decompensation, and reduce chronic end-organ complications. Glycemic control is evaluated through short-term (self-monitoring, continuous glucose monitoring) and long-term (A1c, fructosamine) metrics, enabling near real-time tracking of blood glucose levels and reflecting glycemic control over specific time frames.
Insulin remains the cornerstone of treatment for most patients with type 1 and many...
Insulin remains the cornerstone of treatment for most patients with type 1 and many...
01:24Type II Diabetes II: Pathophysiology
PathophysiologyType 2 diabetes mellitus (T2DM ) is a chronic metabolic disorder characterized by insulin resistance and progressive pancreatic β-cell dysfunction, leading to impaired glucose homeostasis. It results from interactions among genetic predisposition, environmental factors, and metabolic stressors, such as overnutrition and a sedentary lifestyle.Insulin Resistance and Glucose DysregulationEarly T2DM involves insulin resistance in skeletal muscle, adipose tissue, and the liver.